vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and NATIONAL RESEARCH CORP (NRC). Click either name above to swap in a different company.
NATIONAL RESEARCH CORP is the larger business by last-quarter revenue ($35.2M vs $21.2M, roughly 1.7× Autolus Therapeutics plc). NATIONAL RESEARCH CORP runs the higher net margin — 5.1% vs -373.3%, a 378.4% gap on every dollar of revenue. NATIONAL RESEARCH CORP produced more free cash flow last quarter ($6.1M vs $-72.3M).
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
National Research Corporation, doing business as NRC Health, is an American healthcare company which provides healthcare products and subscription-based solutions in United States and Canada. It was founded in 1981, and is based in Lincoln, Nebraska.
AUTL vs NRC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $35.2M |
| Net Profit | $-79.1M | $1.8M |
| Gross Margin | — | — |
| Operating Margin | -337.9% | 13.3% |
| Net Margin | -373.3% | 5.1% |
| Revenue YoY | — | -4.6% |
| Net Profit YoY | 3.6% | -72.6% |
| EPS (diluted) | $-0.30 | $49.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $35.2M | ||
| Q3 25 | $21.2M | $34.6M | ||
| Q2 25 | $20.9M | $34.0M | ||
| Q1 25 | $9.0M | $33.6M | ||
| Q4 24 | — | $36.9M | ||
| Q3 24 | $0 | $35.8M | ||
| Q2 24 | $0 | $35.0M | ||
| Q1 24 | $10.1M | $35.3M |
| Q4 25 | — | $1.8M | ||
| Q3 25 | $-79.1M | $4.1M | ||
| Q2 25 | $-47.9M | $-106.0K | ||
| Q1 25 | $-70.2M | $5.8M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | $-82.1M | $5.7M | ||
| Q2 24 | $-58.3M | $6.2M | ||
| Q1 24 | $-52.7M | $6.4M |
| Q4 25 | — | 13.3% | ||
| Q3 25 | -337.9% | 22.4% | ||
| Q2 25 | -292.6% | 4.7% | ||
| Q1 25 | -726.3% | 25.6% | ||
| Q4 24 | — | 26.0% | ||
| Q3 24 | — | 22.3% | ||
| Q2 24 | — | 25.3% | ||
| Q1 24 | -384.1% | 24.8% |
| Q4 25 | — | 5.1% | ||
| Q3 25 | -373.3% | 11.9% | ||
| Q2 25 | -229.0% | -0.3% | ||
| Q1 25 | -781.1% | 17.2% | ||
| Q4 24 | — | 17.8% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | -522.1% | 18.0% |
| Q4 25 | — | $49.58 | ||
| Q3 25 | $-0.30 | $0.18 | ||
| Q2 25 | $-0.18 | $-0.01 | ||
| Q1 25 | $-0.26 | $0.25 | ||
| Q4 24 | — | $0.27 | ||
| Q3 24 | $-0.31 | $0.24 | ||
| Q2 24 | $-0.22 | $0.26 | ||
| Q1 24 | $-0.24 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $4.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $265.5M | $14.0M |
| Total Assets | $661.9M | $134.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.1M | ||
| Q3 25 | $86.1M | $2.2M | ||
| Q2 25 | $123.8M | $5.3M | ||
| Q1 25 | $95.8M | $2.5M | ||
| Q4 24 | — | $4.2M | ||
| Q3 24 | $657.1M | $3.5M | ||
| Q2 24 | $705.9M | $485.0K | ||
| Q1 24 | $758.5M | $1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $48.7M | ||
| Q2 24 | — | $33.3M | ||
| Q1 24 | — | $35.2M |
| Q4 25 | — | $14.0M | ||
| Q3 25 | $265.5M | $14.3M | ||
| Q2 25 | $346.5M | $21.3M | ||
| Q1 25 | $371.1M | $29.7M | ||
| Q4 24 | — | $31.3M | ||
| Q3 24 | $477.0M | $34.6M | ||
| Q2 24 | $527.8M | $40.2M | ||
| Q1 24 | $582.0M | $36.9M |
| Q4 25 | — | $134.9M | ||
| Q3 25 | $661.9M | $135.7M | ||
| Q2 25 | $721.0M | $141.4M | ||
| Q1 25 | $746.3M | $135.2M | ||
| Q4 24 | — | $132.5M | ||
| Q3 24 | $827.5M | $131.8M | ||
| Q2 24 | $853.6M | $119.1M | ||
| Q1 24 | $901.4M | $120.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | — | 0.95× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $7.2M |
| Free Cash FlowOCF − Capex | $-72.3M | $6.1M |
| FCF MarginFCF / Revenue | -341.2% | 17.2% |
| Capex IntensityCapex / Revenue | 20.8% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 3.99× |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | $15.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.2M | ||
| Q3 25 | $-67.9M | $13.8M | ||
| Q2 25 | $-72.8M | $-1.1M | ||
| Q1 25 | $-75.6M | $6.6M | ||
| Q4 24 | — | $6.4M | ||
| Q3 24 | $-76.7M | $9.4M | ||
| Q2 24 | $-51.1M | $6.8M | ||
| Q1 24 | $-40.5M | $12.0M |
| Q4 25 | — | $6.1M | ||
| Q3 25 | $-72.3M | $10.2M | ||
| Q2 25 | $-80.1M | $-4.1M | ||
| Q1 25 | $-83.8M | $3.7M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | $-86.3M | $7.8M | ||
| Q2 24 | $-51.9M | $1.5M | ||
| Q1 24 | $-41.0M | $7.9M |
| Q4 25 | — | 17.2% | ||
| Q3 25 | -341.2% | 29.4% | ||
| Q2 25 | -382.6% | -12.2% | ||
| Q1 25 | -933.1% | 10.9% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | — | 21.8% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | -406.8% | 22.4% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | 20.8% | 10.4% | ||
| Q2 25 | 34.8% | 8.8% | ||
| Q1 25 | 91.8% | 8.9% | ||
| Q4 24 | — | 12.0% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 15.0% | ||
| Q1 24 | 5.3% | 11.7% |
| Q4 25 | — | 3.99× | ||
| Q3 25 | — | 3.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
